Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.

NCT07229027 · tracked via the Priya Life Science UK tracker
Sponsor
Medialis Ltd
Phase
Observational
Started
2025-11-01
Last updated
2025-11-14

Condition(s) studied

Overweight (BMI > 25)Obesity & Overweight

Study summary

We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patient group 1. Patient is aged ≥18 years at the time of survey completion. 2. Patient has a BMI over 25 (self-reported) 3. Patient is willing to participate in all study activities. 4. Patient is able to read, write, and converse in English. * Healthcare professional participant must meet the following criteria for inclusion in the study: 1. HCP is aged ≥18 years at the time of survey completion. 2. HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25 3. HCP is willing to participate in all study activities. 4. HCP is able to read, write, and converse in English. Exclusion Criteria: A participant who meets any of the following criteria will be excluded from the study: 1. Participants do not have the cognitive capacity to provide informed consent. 2. Participants with severe co-morbidity that might affect study participation.

Primary outcome measure(s)

  • Development of a Disease-Specific Questionnaire — 2 months

Trial sites (1)

FacilityCityRegionStatus
Online recruitment Milton Keynes United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07229027 on ClinicalTrials.gov ↗ ← All trials in the UK